Physician profile
Anna T Davis
NPI 1710111836
$2,692.88
in general payments reported to CMS, 2019-2025
32 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $213 · 2021: $140 · 2022: $401 · 2023: $752 · 2024: $209 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,292 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,291.73 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $514.37 | 2019-2025 | Acessa Provu System, Thinprep 2000 Processor, Aptima |
| Abbvie INC. | $396.04 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $230.05 | 2022-2025 | |
| Amgen INC. | $151.43 | 2019-2020 | |
| Astellas Pharma US INC | $148.99 | 2023-2025 | Veozah |
| Pfizer INC. | $147.76 | 2019-2025 | |
| Myriad Women'S Health, INC. | $136.21 | 2023 | Myrisk |
| Vertical Pharmaceuticals, LLC | $118.64 | 2019 | |
| Amag Pharmaceuticals, INC. | $103.20 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.13 | 2019-2023 | |
| Millicent US INC | $74.07 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Myovant Sciences INC. | $68.79 | 2022 | |
| Duchesnay USA Incorporated | $52.07 | 2019 | |
| Coopersurgical, INC. | $51.36 | 2024-2025 | Paragard T 380a |
| Avion Pharmaceuticals | $43.25 | 2022-2023 | Balcoltra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $41.46 | 2022-2024 | Nexplanon |
| Therapeuticsmd, INC. | $37.91 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $33.59 | 2019-2022 | |
| Biogen, INC. | $27.64 | 2025 | Zurzuvae |
| Radius Health, INC. | $25.79 | 2019 | |
| Microtransponder, INC. | $24.05 | 2025 | |
| Exact Sciences Corporation | $23.87 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $19.27 | 2023 | Myfembree |
| Daiichi Sankyo INC. | $18.16 | 2022 | |
| Axonics, INC. | $17.88 | 2023 | Axonics |
| Mylan Pharmaceuticals INC. | $16.64 | 2022 | |
| Shield Therapeutics INC | $15.95 | 2024 | |
| Allergan, INC. | $14.80 | 2019 | |
| Lupin INC. | $14.74 | 2019 | |
| Masimo Corporation | $14.07 | 2022 | |
| Medicem INC. | $12.85 | 2022 | |
| Exeltis, USA INC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.